HRP20240074T1 - Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem - Google Patents

Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem Download PDF

Info

Publication number
HRP20240074T1
HRP20240074T1 HRP20240074TT HRP20240074T HRP20240074T1 HR P20240074 T1 HRP20240074 T1 HR P20240074T1 HR P20240074T T HRP20240074T T HR P20240074TT HR P20240074 T HRP20240074 T HR P20240074T HR P20240074 T1 HRP20240074 T1 HR P20240074T1
Authority
HR
Croatia
Prior art keywords
suspension
paliperidone palmitate
dose
administration
paliperidone
Prior art date
Application number
HRP20240074TT
Other languages
English (en)
Croatian (hr)
Inventor
Srihari Gopal
Raja Venkatasubramanian
Huybrecht T'jollyn
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75888043&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20240074(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HRP20240074T1 publication Critical patent/HRP20240074T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20240074TT 2020-11-30 2021-05-07 Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem HRP20240074T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063119405P 2020-11-30 2020-11-30
EP21724652.9A EP4025188B1 (en) 2020-11-30 2021-05-07 Dosing regimens associated with extended release paliperidone injectable formulations
PCT/EP2021/062147 WO2022111859A1 (en) 2020-11-30 2021-05-07 Dosing regimens associated with extended release paliperidone injectable formulations

Publications (1)

Publication Number Publication Date
HRP20240074T1 true HRP20240074T1 (hr) 2024-03-29

Family

ID=75888043

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20240074TT HRP20240074T1 (hr) 2020-11-30 2021-05-07 Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem

Country Status (22)

Country Link
US (3) US11304951B1 (cg-RX-API-DMAC7.html)
EP (2) EP4025188B1 (cg-RX-API-DMAC7.html)
JP (2) JP7792959B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250053980A (cg-RX-API-DMAC7.html)
CN (1) CN116583270A (cg-RX-API-DMAC7.html)
AU (3) AU2021386450B2 (cg-RX-API-DMAC7.html)
CA (1) CA3203566A1 (cg-RX-API-DMAC7.html)
DK (1) DK4025188T3 (cg-RX-API-DMAC7.html)
ES (1) ES2973583T3 (cg-RX-API-DMAC7.html)
FI (1) FI4025188T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240074T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065573T2 (cg-RX-API-DMAC7.html)
IL (1) IL303253A (cg-RX-API-DMAC7.html)
LT (1) LT4025188T (cg-RX-API-DMAC7.html)
MX (2) MX2023006366A (cg-RX-API-DMAC7.html)
PL (1) PL4025188T3 (cg-RX-API-DMAC7.html)
PT (1) PT4025188T (cg-RX-API-DMAC7.html)
RS (1) RS65178B1 (cg-RX-API-DMAC7.html)
SI (1) SI4025188T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400077T1 (cg-RX-API-DMAC7.html)
TW (2) TWI877363B (cg-RX-API-DMAC7.html)
WO (1) WO2022111859A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4025188B1 (en) * 2020-11-30 2024-01-10 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
PL4005555T3 (pl) 2020-11-30 2024-09-02 Janssen Pharmaceutica Nv Sposoby zapewniania ponownego zawieszenia preparatów palmitynianu paliperydonu
SI4025187T1 (sl) 2020-11-30 2024-03-29 Janssen Pharmaceutica Nv Režimi odmerjanja, povezani s formulacijami paliperidona za injiciranje s podaljšanim sproščanjem
CN116528836A (zh) 2020-11-30 2023-08-01 詹森药业有限公司 与延长释放帕潘立酮可注射制剂相关的给药方案
MX2024002215A (es) 2021-08-20 2024-05-10 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
CN101163702B (zh) 2005-04-25 2011-09-07 詹森药业有限公司 制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法
CA2655335C (en) * 2007-12-19 2016-09-06 Janssen Pharmaceutica N.V. Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same
US8758780B2 (en) 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
AU2010313290A1 (en) * 2009-10-30 2012-05-17 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
SI2529757T1 (sl) 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata
WO2016157061A1 (en) * 2015-03-31 2016-10-06 Wockhardt Limited Aseptic wet milling process for paliperidone palmitate
DK3744326T3 (da) * 2015-04-07 2024-02-05 Janssen Pharmaceutica Nv Doseringsregime for glemte doser til langtidsvirkende injicerbare paliperidonestere
CN114783258A (zh) 2015-06-19 2022-07-22 詹森药业有限公司 用于药物施用和混合的系统及用于所述系统的适当技术的训练
US20190183896A1 (en) * 2017-12-14 2019-06-20 SpecGx LLC One step milling process for preparing micronized paliperidone esters
EP4025188B1 (en) * 2020-11-30 2024-01-10 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations

Also Published As

Publication number Publication date
KR20250053980A (ko) 2025-04-22
KR20230116013A (ko) 2023-08-03
PT4025188T (pt) 2024-02-29
AU2021386450A9 (en) 2025-03-13
EP4025188B1 (en) 2024-01-10
IL303253A (en) 2023-07-01
DK4025188T3 (da) 2024-03-04
JP7792959B2 (ja) 2025-12-26
ES2973583T3 (es) 2024-06-20
CA3203566A1 (en) 2022-06-02
JP2026027255A (ja) 2026-02-18
AU2026203613A1 (en) 2026-05-28
AU2024204213A1 (en) 2024-07-11
US20260060986A1 (en) 2026-03-05
US20220249495A1 (en) 2022-08-11
KR102794804B1 (ko) 2025-04-10
CN116583270A (zh) 2023-08-11
HUE065573T2 (hu) 2024-06-28
AU2021386450A1 (en) 2023-07-13
PL4025188T3 (pl) 2024-06-17
EP4356966A3 (en) 2024-07-17
TW202222319A (zh) 2022-06-16
RS65178B1 (sr) 2024-03-29
EP4356966A2 (en) 2024-04-24
TW202539685A (zh) 2025-10-16
SI4025188T1 (sl) 2024-03-29
TWI926646B (zh) 2026-05-21
US11304951B1 (en) 2022-04-19
AU2024204213B2 (en) 2026-02-26
AU2021386450B2 (en) 2024-03-21
SMT202400077T1 (it) 2024-03-13
TWI877363B (zh) 2025-03-21
JP2023552329A (ja) 2023-12-15
MX2023006366A (es) 2023-08-07
LT4025188T (lt) 2024-03-12
WO2022111859A1 (en) 2022-06-02
MX2024009188A (es) 2024-08-06
EP4025188A1 (en) 2022-07-13
FI4025188T3 (fi) 2024-02-21

Similar Documents

Publication Publication Date Title
HRP20240086T1 (hr) Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem
FI4025188T3 (fi) Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia
HRP20240800T1 (hr) Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem
JP3623962B2 (ja) ヒドロキソコバラミンの鼻中投与用医薬組成物
HRP20161505T1 (hr) Dostava terapeutskih agensa u cns
AU631711B2 (en) An aerosol preparation of glutathione and a method for augmenting glutathione level in lungs
JP2023552149A5 (cg-RX-API-DMAC7.html)
US20150272876A1 (en) Vitamin b12 nasal spray and method of use
CO6260019A2 (es) Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento
JP2023552329A5 (cg-RX-API-DMAC7.html)
CR6458A (es) Composiciones de valdecoxib
RU2010141542A (ru) Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций
JP2023551009A5 (cg-RX-API-DMAC7.html)
HRP20150438T1 (hr) Uporaba lizosomalne kiselinske lipaze za lijeäśenje deficijencije lizosomalne kiselinske lipaze kod pacijenata
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
IL309340A (en) Dosing regimen for missing doses of paliperidone long-acting injectable esters
JP7523834B2 (ja) 吸入型血管作動性腸ポリペプチドの新しい投与計画
FI3990005T3 (fi) Pegyloitu kystationiini-beta-syntaasi entsyymihoitoa varten homokystinurian hoitamiseksi
JP2020158544A5 (cg-RX-API-DMAC7.html)
CA1317881C (en) Aerosol compositions for nasal delivery of vitamin b__
FI3389717T3 (fi) Neoadjuvanttihoito virtsarakon syöpää varten
IL310909A (en) Dosing regimens associated with extended release paliperidone injectable formulations
JP2023520703A5 (cg-RX-API-DMAC7.html)
US11497747B2 (en) Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections
JP2022176154A5 (cg-RX-API-DMAC7.html)